Tesamorelin
Stabilized GHRH analog for metabolic and composition research.
Tesamorelin
Background
Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH), modified at the N-terminus to resist enzymatic degradation. It acts on pituitary GHRH receptors to stimulate endogenous, pulsatile secretion of growth hormone, and has been studied most extensively for its effect on visceral adipose tissue.
It is the only GHRH analog to have completed large randomized controlled trials, conducted in patients with HIV-associated lipodystrophy, where it reduced visceral adipose tissue and liver fat. This represents a comparatively robust clinical evidence base relative to most research peptides.
Selected literature
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.
- Clemmons DR, et al. Tesamorelin and visceral adiposity: pooled analysis. Journal of Acquired Immune Deficiency Syndromes. 2015.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
Tesamorelin is marketed as Egrifta(R) and Egrifta SV(R) by Theratechnologies Inc. Those trademarks are the property of their owner. Catalyst Research Labs is not affiliated with, endorsed by, or sponsored by Theratechnologies. Supplied as reference material only.
